









Markets
/
Stocks
/
nasdaq-bmea
/

Biomea Fusion Inc

BMEA

1.950USD

-0.130-6.25%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

113.35MMarket Cap

LossP/E TTM



Biomea Fusion Inc

1.950

-0.130-6.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

262 / 506

Overall Ranking

428 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

8.000

Target Price

+284.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 69.17.

Overvalued

The company’s latest PE is -0.65, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 30.74M shares, decreasing 7.27% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.88M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.44.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.69, which is 108.81% below the recent high of -1.45 and -513.02% above the recent low of -4.24.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 262/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.25, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Biomea Fusion Inc is 7.00, with a high of 16.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.25

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

8.000

Target Price

+284.62%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Biomea Fusion Inc

BMEA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 5.51, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 2.22 and the support level at 1.83, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.51

Change

-0.61

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.016

Buy

RSI(14)

53.421

Neutral

STOCH(KDJ)(9,3,3)

64.928

Neutral

ATR(14)

0.123

Low Volatility

CCI(14)

67.270

Neutral

Williams %R

46.508

Neutral

TRIX(12,20)

0.507

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.994

Sell

MA10

1.939

Buy

MA20

1.915

Buy

MA50

1.809

Buy

MA100

1.860

Buy

MA200

2.678

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 51.66%, representing a quarter-over-quarter decrease of 9.20%. The largest institutional shareholder is The Vanguard, holding a total of 1.88M shares, representing 3.16% of shares outstanding, with 18.30% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

5.44M

Heights Capital Management, Inc.

4.45M

Cormorant Asset Management, LP

3.57M

Butler (Thomas Andrew)

2.97M

Erdtmann (Rainer M)

2.53M

Aisling Capital Management LP

798.76K

The Vanguard Group, Inc.

Star Investors

1.38M

-1.65%

Woodline Partners LP

240.84K

BlackRock Institutional Trust Company, N.A.

1.96M

-2.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 2.97, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.15. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.